PortalPublikationenHigh incidence of tardive dyskinesia in older outpatients on...

High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.

Standard

High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. / Harris, M J; Panton, D; Caligiuri, M P; Krüll, Andreas; Tran-Johnson, T K; Jeste, D V.

in: PSYCHOPHARMACOL BULL, Jahrgang 28, Nr. 1, 1, 1992, S. 87-92.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Harris, MJ, Panton, D, Caligiuri, MP, Krüll, A, Tran-Johnson, TK & Jeste, DV 1992, 'High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.', PSYCHOPHARMACOL BULL, Jg. 28, Nr. 1, 1, S. 87-92. <http://www.ncbi.nlm.nih.gov/pubmed/1609047?dopt=Citation>

APA

Harris, M. J., Panton, D., Caligiuri, M. P., Krüll, A., Tran-Johnson, T. K., & Jeste, D. V. (1992). High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. PSYCHOPHARMACOL BULL, 28(1), 87-92. [1]. http://www.ncbi.nlm.nih.gov/pubmed/1609047?dopt=Citation

Vancouver

Harris MJ, Panton D, Caligiuri MP, Krüll A, Tran-Johnson TK, Jeste DV. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics. PSYCHOPHARMACOL BULL. 1992;28(1):87-92. 1.

Bibtex

@article{85201b15d4db4c16be46b6a6df7e94e8,
title = "High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.",
abstract = "We are conducting a prospective study of tardive dyskinesia (TD) in psychiatric patients over age 45, a large proportion of whom have had less than 1 month of total lifetime neuroleptic exposure. Patients are treated with the lowest effective dose of either haloperidol (usually 1-3 mg daily) or thioridazine (usually 25-75 mg daily). Patients are reexamined 1 month and 3 months after initial assessment and then at 3-month intervals. To date, a total of 68 patients (mean age 69.5 years) have been evaluated. Survival analysis showed a 27 percent cumulative incidence of TD (the 95% confidence interval being 14% to 40%) with 6 months of neuroleptic treatment in the study. The TD and non-TD patients did not differ on demographic and baseline clinical measures. Instrumental assessment showed that a greater proportion of TD patients had subclinical evidence of dyskinesia prior to the institution of neuroleptics, compared with non-TD patients.",
keywords = "Humans, Male, Female, Middle Aged, Risk Factors, Prospective Studies, Age Factors, Follow-Up Studies, Incidence, Dyskinesia, Drug-Induced/*epidemiology, Haloperidol/*adverse effects, Thioridazine/*adverse effects, Humans, Male, Female, Middle Aged, Risk Factors, Prospective Studies, Age Factors, Follow-Up Studies, Incidence, Dyskinesia, Drug-Induced/*epidemiology, Haloperidol/*adverse effects, Thioridazine/*adverse effects",
author = "Harris, {M J} and D Panton and Caligiuri, {M P} and Andreas Kr{\"u}ll and Tran-Johnson, {T K} and Jeste, {D V}",
year = "1992",
language = "English",
volume = "28",
pages = "87--92",
number = "1",

}

RIS

TY - JOUR

T1 - High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.

AU - Harris, M J

AU - Panton, D

AU - Caligiuri, M P

AU - Krüll, Andreas

AU - Tran-Johnson, T K

AU - Jeste, D V

PY - 1992

Y1 - 1992

N2 - We are conducting a prospective study of tardive dyskinesia (TD) in psychiatric patients over age 45, a large proportion of whom have had less than 1 month of total lifetime neuroleptic exposure. Patients are treated with the lowest effective dose of either haloperidol (usually 1-3 mg daily) or thioridazine (usually 25-75 mg daily). Patients are reexamined 1 month and 3 months after initial assessment and then at 3-month intervals. To date, a total of 68 patients (mean age 69.5 years) have been evaluated. Survival analysis showed a 27 percent cumulative incidence of TD (the 95% confidence interval being 14% to 40%) with 6 months of neuroleptic treatment in the study. The TD and non-TD patients did not differ on demographic and baseline clinical measures. Instrumental assessment showed that a greater proportion of TD patients had subclinical evidence of dyskinesia prior to the institution of neuroleptics, compared with non-TD patients.

AB - We are conducting a prospective study of tardive dyskinesia (TD) in psychiatric patients over age 45, a large proportion of whom have had less than 1 month of total lifetime neuroleptic exposure. Patients are treated with the lowest effective dose of either haloperidol (usually 1-3 mg daily) or thioridazine (usually 25-75 mg daily). Patients are reexamined 1 month and 3 months after initial assessment and then at 3-month intervals. To date, a total of 68 patients (mean age 69.5 years) have been evaluated. Survival analysis showed a 27 percent cumulative incidence of TD (the 95% confidence interval being 14% to 40%) with 6 months of neuroleptic treatment in the study. The TD and non-TD patients did not differ on demographic and baseline clinical measures. Instrumental assessment showed that a greater proportion of TD patients had subclinical evidence of dyskinesia prior to the institution of neuroleptics, compared with non-TD patients.

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Risk Factors

KW - Prospective Studies

KW - Age Factors

KW - Follow-Up Studies

KW - Incidence

KW - Dyskinesia, Drug-Induced/epidemiology

KW - Haloperidol/adverse effects

KW - Thioridazine/adverse effects

KW - Humans

KW - Male

KW - Female

KW - Middle Aged

KW - Risk Factors

KW - Prospective Studies

KW - Age Factors

KW - Follow-Up Studies

KW - Incidence

KW - Dyskinesia, Drug-Induced/epidemiology

KW - Haloperidol/adverse effects

KW - Thioridazine/adverse effects

M3 - SCORING: Journal article

VL - 28

SP - 87

EP - 92

IS - 1

M1 - 1

ER -